NEW YORK (GenomeWeb News) – Swiss biopharmaceutical research supply company Lonza Group has closed its acquisition of Amaxa, a provider of cell research and transfection technologies, for an undisclosed sum.
Lonza sells products for cell-based research, cell therapy manufacturing, and other ingredients for the chemical and biotech markets. The firm, which first agreed to the deal in late May, said it plans to begin integrating Amaxa, including its 160 employees, into its operations immediately.
Amaxa offers technologies for use in gene transfer, gene silencing, and gene-based medicine, and a method for transferring DNA or siRNA directly into the nucleus of primary cells and cell lines.
Lonza said in May that the purchase will enhance profit margins and growth for the Lonza Bioscience division.